These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Distribution of angiotensin converting enzyme in human tissues. van Sande ME; Scharpé SL; Neels HM; Van Camp KO Clin Chim Acta; 1985 Apr; 147(3):255-60. PubMed ID: 2581725 [TBL] [Abstract][Full Text] [Related]
34. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype. van Esch JH; van Gool JM; de Bruin RJ; Payne JR; Montgomery HE; Hectors M; Deinum J; Dive V; Jan Danser AH J Hypertens; 2008 Apr; 26(4):706-13. PubMed ID: 18327080 [TBL] [Abstract][Full Text] [Related]
35. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme. Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712 [TBL] [Abstract][Full Text] [Related]
36. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Michaud A; Williams TA; Chauvet MT; Corvol P Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274 [TBL] [Abstract][Full Text] [Related]
37. Assay of angiotensin I-converting enzyme-inhibiting activity based on the detection of 3-hydroxybutyric acid. Lam le H; Shimamura T; Sakaguchi K; Noguchi K; Ishiyama M; Fujimura Y; Ukeda H Anal Biochem; 2007 May; 364(2):104-11. PubMed ID: 17386920 [TBL] [Abstract][Full Text] [Related]